Phase 2 Trial Signals Potential for GLP-1R Agonists to Boost Outcomes in LVO Stroke Patients
A recent phase 2 randomized trial suggests that glucagon-like peptide-1 receptor (GLP-1R) agonists may offer neuroprotective benefits for individuals with large vessel occlusion (LVO) strokes who are receiving reperfusion therapy. Published in Nature Communications in 2025, the study examined whether GLP-1R agonists, a drug class commonly used to treat diabetes, could enhance recovery when used alongside standard reperfusion procedures.
In the trial, participants with LVO strokes were assigned to receive the usual reperfusion treatment plus a GLP-1R agonist, while a control group received standard care alone. Researchers tracked key clinical outcomes, including neurological improvement and safety indicators. The results showed that those treated with GLP-1R agonists experienced measurable advantages over the control group. Nevertheless, the investigators caution that these findings need validation in larger, more diverse populations to establish consistent efficacy and safety.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For feedback or suggestions, please contact us.
Date: December 14, 2025
©www.geneonline.com All rights reserved. Collaborate with us: emailprotected
